ReviewAmerican journal of hematology2026
Extramedullary Disease-Achilles Heel in Myeloma?
Review in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement.Blood advances · 2026Article
- Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.British journal of haematology · 2026Observational
- When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era.Cancers · 2026Review
- High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.HemaSphere · 2026Article
- Acute Pancreatitis as a Rare Initial Presentation of Plasma Cell Leukemia in a Young Male: A Case Report.Cureus · 2026Article
- Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion molecules, heterogeneous genetic and epigenetic changes, and a solid tumor-like architecture within the microenvironment. Although the introduction of advanced imaging techniques and immunotherapy has led to improved detection and more promising outcomes and regimens, respectively, more prospective studies dedicated to true EMD are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.